EUDA launches gene-modulating supplement; sending shares up premarket

* Shares of EUDA Health Holdings (NASDAQ:EUDA [https://seekingalpha.com/symbol/EUDA]) rose 10% in the premarket trade on Tuesday after the company announced that it has secured exclusive global distribution rights for a next-generation immune health supplement from Singapore biotech, Chemokine Pte. Ltd.
* Euda Helixé, the supplement, uses epigenetic gene modulation to boost metabolism, energy, skin regeneration, and longevity.
* Initial sales will focus on Singapore, Malaysia, and China, with plans to expand globally.
* Company targets 500,000 unit sales over the next 12 months.
* The product was developed by Prof. Kah Meng Lim, a molecular medicine expert, formerly with Singapore's national R&D agency, A*STAR.
* "The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. " CEO Alfred Lim, said in a statement.
* EUDA +10.48% premarket to $2.95
* Source: Press Release [https://seekingalpha.com/pr/20211394-euda-expands-wellness-product-portfolio-with-a-next-generation-immune-health-supplement]

MORE ON EUDA HEALTH HOLDINGS LIMITED

* Seeking Alpha’s Quant Rating on EUDA Health Holdings Limited [https://seekingalpha.com/symbol/EUDA/ratings/quant-ratings]
* Historical earnings data for EUDA Health Holdings Limited [https://seekingalpha.com/symbol/EUDA/earnings]
* Financial information for EUDA Health Holdings Limited [https://seekingalpha.com/symbol/EUDA/income-statement]